The anabolic effect of Formebolone on the retention of nitrogen, phosphorus and calcium in adult male volunteers was evaluated over a period of 21 days. The study was divided into a pre-dosc period to establish baseline data, a period where the drug was given daily followed by a third period after treatment had ceased to investigate whether the effects were in any way prolonged. Formebolone was well tolerated and showed a positive effect on nitrogen balance and bodyweight change in all subjects. The effects on calcium and phosphorus balance were less clear-cut but indicated increased retention of both elements.
D'AtriGGalimbertiEGomarascaP (1973) Increased enzymatic activity induced by formyldienolone. III. Alkaline phosphatase. Bollettino Chimico Farmaceutico112, 620
3.
De MarchiGD'AtriGScolasticoC (1975) Urinary Metabolites of 2-formyl-17(α)-methylandrosta-1, 4-diene-11(α)-dihydroxy-3-one in the rat, Arzneimittel Forschung. (in press).
4.
De MarchiGD'AtriGScolasticoC (1973) Absorption, distribution and excretion of 2-formyl-17α methylandrosta-1,4-dienc-11α.-17β-dihydroxy-3-one. Arzneimittel Forschung (Drug Res.)23, 1583
5.
EspositoRPluvioMGiordanoC (1975) Anabolic agents in kidney disease: The effect of Formebolone on protein synthesis in patients with renal insufficiency or nephrosis. Current Medical Research and Opinion3, 43
6.
Fawcett & Scott (1960) Specific parameters measured urease/Berthelot reaction. Journal of Clinical Pathology13, 156
7.
GalimbertiECeruttiS (1972) Study on the sub-acute toxicity and the eventual carcinogenic action of formyldienolone. Gazzetta Internazionale di Medicina e Chirurgia24, 77, 2312
8.
GalimbertiED'AtriGCeruttiS (1973) Increased Enzymatic activity induced by formyldienolone. II Diaphorases. Bollettino Chimico Farmaceutico112, 370
9.
GomarascaM (1971) 2-Formyl-11(α)-hydroxy-δ1-methyltcstosteronc; a new water-soluble anabolic steroid. Minerva Medica62, 842
10.
GomarascaPGalimbertiECeruttiS (1972) Increased enzymatic activity induced by formyldienolone, I. Succinic dehydrogenase. Bollettino Chimico Farmaceutico111, 731
11.
GomarascaPDi StefanoA (1974) A study on the vaginal cytology during and after treatment with an anabolic steroid. Minerva Pediatrica26, 377
12.
IsidoriADonderoF (1970) Studio della funzione ipofisiaria in soggetti normali trattati con uno steroide anabolizzante. Minerva Medica61, 5364
13.
MolinoNBelluardoCRossoB (1973) Dysprotidemic syndromes in geriatrics and their treatment with a new anabolic steroid derived from androstane, 2-formyl-11(α)-hydroxy-δ1-methylteslosterone. Our clinical experience. La Clinica Terapeutica. 66, 167
14.
PardiniCTerriniF (1971) Clinical studies on a new anabolic steroid: 2-formyl-17(α) 17(α))diol-3-one. La Clinica Terapeutica58, 4
15.
Piatti & Pozzi (1975) Sperimentazione con 2-formiI-17(α)-metilandrosta-1, 4-dienc-11(α), 17(β)-diol-3-one in clinical geriatrica. La Clinica Terapeutica (in press).
16.
TravellaG (1971) Toxicological research on a new steroid with anabolic activity, 2-formyl-17(α)-methylandrosta-1, 4-dicne-11(α) 17(β)-diol-3-onc (Esiclene)Gazzetta internazionale di Medicina e Chirurgia76, 400
17.
VaccariALiviniE (1971) Nitrogen, calcium and phosphorus balance in man following oral treatment with a new anabolic steroid. 2-formyl-17(α) methylandrosta-1, 4-diene-11-(α) 17(β) diol-3 one. Minerva Medica62, 846
